Evolus, Inc. (EOLS)
(Delayed Data from NSDQ)
$11.50 USD
+0.04 (0.35%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value F Growth D Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Do Options Traders Know Something About Evolus (EOLS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
EOLSPositive Net Change
medical
Are Options Traders Betting on a Big Move in Evolus (EOLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
EOLSPositive Net Change
medical
Is the Options Market Predicting a Spike in Evolus (EOLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
EOLSPositive Net Change
medical
Why Earnings Season Could Be Great for Evolus (EOLS)
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
EOLSPositive Net Change
medical
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
IARTNegative Net Change BIOCNegative Net Change CLRBNegative Net Change EOLSPositive Net Change
earnings medical
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
EOLSPositive Net Change
medical
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
EOLSPositive Net Change
medical
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
AZNNegative Net Change AGNPositive Net Change ABBVNegative Net Change EOLSPositive Net Change
earnings pharmaceuticals
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
ABBVNegative Net Change AGNPositive Net Change RVNCNegative Net Change EOLSPositive Net Change
pharmaceuticals
What's in Store for Flexible Solutions (FSI) in Q2 Earnings?
by Zacks Equity Research
Our proven model does not show that Flexible Solutions (FSI) is likely to beat estimates this quarter.
FSINegative Net Change ACBNegative Net Change EOLSPositive Net Change IAANegative Net Change
basic-materials
Barrick (GOLD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong performances from Loulo-Gounkoto and Veladero likely to drive Barrick's (GOLD) Q2 results.
GOLDNegative Net Change ANFNegative Net Change EOLSPositive Net Change IAANegative Net Change
basic-materials gold
Advance Auto Parts (AAP) to Post Q2 Earnings: What's Up?
by Zacks Equity Research
Advance Auto Parts (AAP) Q2 results to gain on footprint expansion. However, high capital expenditures and tough competition make surprise prediction difficult.
AAPNegative Net Change ANFNegative Net Change IAANegative Net Change EOLSPositive Net Change
auto-tires-trucks
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
SYKNegative Net Change BSXPositive Net Change MDTNegative Net Change GWPHNegative Net Change EOLSPositive Net Change CGCNegative Net Change
earnings medical
Will Evolus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Evolus.
EOLSPositive Net Change
medical
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
ABBVNegative Net Change AGNPositive Net Change RVNCNegative Net Change EOLSPositive Net Change
pharmaceuticals
Allergan Up As Analyst Statement Sparks Business Split Rumors
by Zacks Equity Research
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.
LLYNegative Net Change AGNPositive Net Change BHCPositive Net Change EOLSPositive Net Change
pharmaceuticals
Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.
HOLXNegative Net Change NSTGNegative Net Change ACBNegative Net Change EOLSPositive Net Change
earnings medical
Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?
by Zacks Equity Research
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
NSTGNegative Net Change CVSNegative Net Change EOLSPositive Net Change ACBNegative Net Change
earnings medical
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
ZBHPositive Net Change NSTGNegative Net Change EOLSPositive Net Change ACBNegative Net Change
medical
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
NSTGNegative Net Change LHNegative Net Change ACBNegative Net Change EOLSPositive Net Change
medical
Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
by Zacks Equity Research
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
CFMSNegative Net Change NSTGNegative Net Change ACBNegative Net Change EOLSPositive Net Change
medical
Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?
by Zacks Equity Research
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
HRCNegative Net Change NSTGNegative Net Change EOLSPositive Net Change ACBNegative Net Change
earnings medical
Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
by Zacks Equity Research
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
NSTGNegative Net Change BAXPositive Net Change PRGONegative Net Change EOLSPositive Net Change
earnings medical
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
AGNPositive Net Change EWNegative Net Change AIMTNegative Net Change EXASNegative Net Change EOLSPositive Net Change
medical
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
AGNPositive Net Change EWNegative Net Change EXASNegative Net Change AIMTNegative Net Change EOLSPositive Net Change
biotechs pharmaceuticals